SHR-A2102

· Shanghai Hengrui Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for SHR-A2102, covering 2024-11-12 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer [Phase 3]

See pricing